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Molecular mechanisms of diabetic renal hypertrophy. Altered Although the Papyrus Ebers, which dates to approxi-
growth of renal cells is one of the early abnormalities detected mately 1500 B.C., contains what is thought to be the
after the onset of diabetes. Cell culture studies whereby renal first reference to diabetes mellitus [1], Richard Bright
cells are exposed to high glucose concentrations have provided
(1789–1858) often receives credit for the clinical-patho-a considerable amount of insight into mechanisms of growth.
logical correlation that albuminuria reflects serious af-In the glomerular compartment, there is a very early and self-
fliction of the kidney in diabetes mellitus [2]. The Frenchlimited proliferation of mesangial cells with subsequent hyper-
trophy, whereas proximal tubular cells primarily undergo hy- physician Pierre-Franc¸ois-Olivier Rayer (1793–1867),
pertrophy. There is overwhelming evidence from in vivo and known for his outstanding three-volume textbook on
cell culture studies that induction of the transforming growth renal disease, was presumably the first to describe dia-
factor-b (TGF-b) system mediates the actions of high ambient
betic glomerular hypertrophy [3, 4]. He wrote, “In diabe-glucose and that this system is pivotal for the hypertrophy of
tes, one finds hypertrophy of the renal cortex . . . withoutmesangial and tubular cells. Other factors such as hemody-
namic forces, protein glycation products, and several mediators any abnormality except hypertrophy . . . the vessels are
(for example, angiotensin II, endothelin-1, thromboxane, and enlarged and the Malpighian corpuscles are much more
platelet-derived growth factor) may further amplify the synthe- prominent” [4]. Elliott P. Joslin (1869–1962), one of the
sis of TGF-b and/or the expression of its receptors in the first clinicians to specialize in the treatment of diabeticdiabetic state. Cellular hypertrophy can be characterized by
patients, wrote foresightedly in 1917, “The renal compli-cell cycle arrest in the G1 phase. The molecular mechanism
cations of diabetes have been unimportant in the past, butarresting mesangial cells in the G1 phase of the cell cycle is the
induction of cyclin-dependent kinase (CdK) inhibitors such as with the prolongation of life which modern treatment is
p27Kip1 and p21, which bind to and inactivate cyclin-CdK com- bringing about they will deserve attention” [5]. This al-
plexes responsible for G1-phase exit. High-glucose–induced acti- most prophetic statement, made just five years before
vation of protein kinase C and stimulated TGF-b expression the introduction of insulin into clinical practice, has un-appear to be essential for stimulated expression of p27Kip1. In
fortunately been proven correct because more than oneaddition, a decreased turnover of protein caused by the inhibi-
third of patients entering maintenance dialysis today suf-tion of proteases contributes to hypertrophy. The development
of irreversible renal changes in diabetes mellitus such as glo- fer from diabetic nephropathy.
merulosclerosis and tubulointerstitial fibrosis is always pre- Diabetic nephropathy encompasses discrete structural
ceded by the early hypertrophic processes in the glomerular alterations, including renal hypertrophy, thickening of
and the tubular compartments. It may still be debated whether
basement membranes, and progressive glomerular accu-diabetic renal hypertrophy will inevitably lead to irreversible
mulation of extracellular matrix components [6]. Ad-fibrotic changes in the absence of other factors such as altered
vanced diabetic glomerulopathy is commonly character-intraglomerular hemodynamics and genetic predisposition.
Nevertheless, understanding cellular growth on a molecular ized by diffuse glomerulosclerosis and may sometimes
level may help design a novel therapeutic approach to prevent exhibit a distinctive morphological appearance, namely,
or treat diabetic nephropathy effectively. the nodular form of glomerulosclerosis, as first described
by Kimmelstiel and Wilson in 1936 [7]. However, the
earliest renal feature of diabetes mellitus is characterized
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by generalized renal growth [8–11]. Extensive morpho-cell cycle, glucose, cyclin.
metric studies performed in the early 1970s on kidneys
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earliest pathological alterations [6, 8–11]. Tubuloepithel- are always preceded by the early hypertrophic processes
in the glomerular and tubular compartments [6]. It isial hypertrophy and tubular basement membrane thick-
ening also occur very early in the course of diabetic renal debatable whether or not these hypertrophic processes
will inevitably lead to irreversible fibrotic changes ininvolvement and are most likely the precursors of the
later irreversible changes in the tubulointerstitial archi- humans, but experimental animal models provide ample
evidence that this may indeed be the case. Thus, glomer-tecture leading to tubular atrophy and interstitial fibrosis
[6, 9]. Although originally described in type 1 diabetes, ular growth processes always precede glomerulosclerosis
in experimental diabetic renal disease and renal ablationit is currently increasingly recognized that there are no
substantial differences between types 1 and 2 diabetes models [19, 25]. Parallel observations have been made
for the tubulointerstitial compartment in which the initialwith respect to these morphological changes, including
renal growth [12–16]. This review focuses on some recent adaptive tubular hypertrophy is often followed by atro-
phy of epithelial cells and interstitial fibrosis [26, 27].advancements in understanding the molecular mecha-
nisms of diabetic renal hypertrophy and the potential Part of this association between growth and fibrogenesis
may be due to the fact that similar networks of cytokineslink to irreversible renal failure and will summarize the
growing evidence of the involvement of relevant growth and growth factors that induce cellular hypertrophy can
also stimulate extracellular matrix synthesis and deposi-factors in this link.
tion [28–31]. An archetypal factor of great clinical impor-
tance is the vasoactive peptide angiotensin II (Ang II); in
IS RENAL GROWTH IMPORTANT IN
addition to its hemodynamic properties, it exerts potent
THE PATHOGENESIS OF
effects on several renal cell types, including stimulation
DIABETIC NEPHROPATHY?
of growth (hypertrophy and/or proliferation) as well as
Glomerular hypertrophy in diabetes mellitus is associ- increased synthesis of extracellular matrix proteins [30,
ated with an increase in the glomerular filtration rate, 31]. As will be delineated in detail later in this article,
mainly caused by increased plasma flow and glomerular hyperglycemia, the hallmark of diabetes mellitus, can
capillary hydrostatic pressure [17–19]. The relationships itself induce several growth factors and up-regulate their
between these glomerular hemodynamic alterations to receptors in renal cells, which, in turn, mediate the stimu-
growth processes are intimately interwoven [20]. Glo- lus for both growth and the production of extracellular
merular hypertrophy in diabetes mellitus results in a matrix proteins [32, 33]. It is also very likely that hyper-
substantial increase in the overall filtration surface area. glycemia and Ang II exert additive hypertrophic and
The resultant increase in the ultrafiltration coefficient prosclerotic effects. Because cells undergoing hypertro-
can further enhance glomerular hyperfiltration [19, 21]. phy can theoretically have a significant increase in mito-
The mechanistic link between high intraglomerular pres- chondrial oxygen consumption, the resultant stimulation
sure and vascular injury has not been directly established, in oxygen radical formation can lead to lipid peroxida-
but could be based on direct pressure injury to the mes- tion and can accentuate the renal injury [34, 35]. Further-
angium and the endothelium or on increased wall ten- more, cells in their growth phase may release vasoactive
sion, leading to altered capillary wall structure and func- factors, which could impair capillary blood flow to subor-
tion. The latter could be exacerbated by the increased dinate vascular beds; this may contribute to ischemic/
glomerular size seen in diabetes. The increased diameter fibrotic changes [31].
of the glomerular capillary early in the course of diabetes Associations between renal growth and the subse-
may confer a mechanical disadvantage through the La- quent development of irreversible loss of renal function
Place relationship (tension 5 transmural pressure 3 ves- have long been suspected in the course of diabetic ne-
sel radius). Through this relationship, increased capillary phropathy [10, 11, 36]. In a seminal study in the field,
diameter would increase wall tension, which may be an Mauer et al investigated structural-functional relation-
injurious component of the diabetes-induced renal en- ships in a cross-section of patients with type 1 diabetes
largement. As described later in this article, shear stress [36]. They found a close correlation between mesangial
and mechanical strain resulting from altered glomerular expansion, which is partly generated by abnormal growth
hemodynamics may indirectly, through the autocrine of mesangial cells in addition to increased extracellular
and/or paracrine release of cytokines and growth factors, matrix components, and clinical manifestations of dia-
trigger growth effects in glomerular cells [20, 22]. In betic nephropathy such as albuminuria, hypertension,
addition, mechanical stretch may more directly influence and a decreased glomerular filtration rate [36]. In paral-
cell cycle progression and extracellular matrix expression lel, a relationship between tubulointerstitial lesions in
of resting glomerular cells [23, 24]. diabetes and impaired renal function has also been ap-
Several observations clearly indicate that the develop- preciated [37, 38]. For many years, the importance of
ment of irreversible renal changes in diabetes mellitus, tubulointerstitial injury has been ignored, and only re-
cently has its important contribution to the onset andsuch as glomerulosclerosis and tubulointerstitial fibrosis,
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progression of renal failure become generally accepted. vented the early proliferation of mesangial cells, a-actin
expression, and the macrophage/monocyte infiltration.Because the tubulointerstitium comprises the bulk of the
kidney [39, 40], tubular hypertrophy is quantitatively A significant increase in mesangial cell proliferation was
reported by Mahadevan et al in rats 21 days after strepto-responsible for the largest component of renal enlarge-
ment in diabetes mellitus [40, 41]. Thus, it is evident that zotocin-induced diabetes compared with controls [45].
both glomerular and tubulointerstitial growth processes
precede the development of diabetic renal disease
MESANGIAL CELL GROWTH IN CULTURE[36, 37].
To discern the relative role of local metabolic changes
from systemic or hemodynamic alterations (for example,
DEVELOPMENT OF stretch, which may modulate mesangial cell growth in
DIABETIC HYPERTROPHY vivo), we developed a cell culture approach to assess
Studies of animals made diabetic with streptozotocin mesangial cell growth after exposure to high d-glucose
have provided evidence that cellular growth associated concentration [46]. Raising the medium glucose concen-
with diabetic nephropathy is a dynamic process [9, 42– tration from 100 to 450 mg/dl had a biphasic effect on
44]. Renal cells can, in general, undergo either prolifera- growth of cultured mouse mesangial cells. It stimulated
tion or hypertrophy, two totally different growth re- cell proliferation early (at 24 to 48 hr of incubation) but
sponses [41]. A distinct renal cell exposed to a stimulus caused an antiproliferative effect thereafter (at 72 to 96
such as the diabetic milieu may exhibit one or the other hr) [46]. These responses were attributed to enhanced
growth response at different times. In addition, the vari- intracellular glucose metabolism and not to increased
ous cell types along the nephron may behave differently extracellular osmolality. The inhibition of proliferation
in diabetes mellitus (proliferation vs. hypertrophy), de- by prolonged incubation in high glucose has also been
pending on their intrinsic genetic program, the concen- reported in cultured human mesangial cells [47, 48]. The
tration of growth factors in the local microenvironment, early phase of glucose-induced proliferation was associ-
and the presence of growth factor receptors on their cell ated with increased expression of the immediate early
surfaces [40, 41]. genes c-myc and Egr-1 as well as with the induction
Early studies showed that diabetic rats exhibit a 15% of PCNA [46], perhaps stimulated by the activation of
increment of whole kidney weight within 72 hours of platelet-derived growth factor-B (PDGF-B) and/or its
induction with streptozotocin [9, 10]. More detailed stud- b-receptor [32, 44, 46]. As is described in detail later in
ies by Romen and Takahashi applying autoradiography this article, the late phase of glucose-induced inhibition
after [3H]-thymidine infusion and electron microscopic of proliferation in our studies was mediated by the bioac-
morphometry indicated that glomerular enlargement is tivation of endogenous transforming growth factor-b
accompanied by glomerular cell proliferation in the early (TGF-b). This correlated with the emergence of cellular
phase of streptozotocin-induced diabetes in rats [42]. In hypertrophy of mouse mesangial cells, that is, after the
contrast, other investigators found no differences in the phase when mitosis was inhibited [46]. Thus, in vivo
incorporation of thymidine into glomerular nuclei when studies and cell culture experiments both suggest that
comparing diabetic to control rats [43]. This apparent the predicted evolution of diabetic glomerulopathy is
contradiction may be resolved by the observation that comprised of an early, self-limited degree of mesangial
proliferation occurs early and transiently, during a nar- cell proliferation, followed by the development of hyper-
row window after induction of diabetes [44]. Young et trophy of these cells that herald the slow progression
al have meticulously quantitated glomerular prolifera- into glomerulosclerosis.
tion at various time points in experimentally induced
diabetic kidney disease using a panel of antibodies [44].
GROWTH OF OTHER RENAL CELLS IN THEBy staining for the proliferating cell nuclear antigen
DIABETIC MILIEU(PCNA), they found a prominent but self-limited mesan-
gial cell proliferation that peaked at day 3 after induction Growth of other glomerular cells besides mesangial
cells may contribute to overall glomerular enlargementof diabetes with streptozotocin and returned to baseline
after 30 days. This proliferation of mesangial cells was in diabetes mellitus (Table 1). An increase in number
and length of capillaries, a form of neovascularization,associated with de novo expression of a-smooth muscle
actin, an activation marker of the proliferative mesangial has been described in compensatory glomerular growth,
including that occurring in diabetes mellitus [49–52]. Ancell phenotype [44]. In addition, an infiltration of prolif-
erating macrophages/monocytes reached peak values at increase of total length of glomerular capillaries by 30%
at day 4 after experimental induction of diabetes in ratsday 30 after diabetes induction and contributed only a
minor extent to the early (day 3) overall glomerular was reported by Osterby and Gundersen [50]. A signifi-
cant increase in total surface area of capillaries was re-proliferation [44]. Insulin treatment of diabetic rats pre-
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Table 2. Growth factors, chemokines, and vasoactive substancesTable 1. Factors contributing to glomerular enlargement
in diabetic glomerulopathy implicated in the growth processes of diabetic nephropathy
Growth factors/cytokinesGrowth of glomerular cells
Early mesangial cell proliferation with subsequent cellular Transforming growth factor-beta (TGF-b)
Platelet-derived growth factor-B (PDGF-B)hypertrophy
Increase in glomerular capillary size and number Insulin-like growth factor-I (IGF-I)
Hepatocyte growth factor (HGF)Proliferation/hypertrophy of glomerular endothelial cells?
Hypertrophy of podocytes?
Chemokines
Interleukin-8 (IL-8)Accumulation of extracellular matrix
Mesangial matrix expansion Monocyte chemotactic peptide-1 (MCP-1)
Basement membrane thickening
Vasoactive substances
Angiotensin II (Ang II)Hemodynamic factors
Increased intraglomerular pressure Endothelin-1 (ET-1)
Prostanoids (for example, thromboxane)Increased capillary wall tension
ported by Nyengaard and Rasch in rats at day 10 after contrast to murine mesangial cells in culture, a high glu-
induction of diabetes [51]. A recent study, however, cose concentration does not stimulate proliferation of
found no evidence for an increase in total glomerular cultured murine proximal tubular cells [62]; instead,
capillary surface area in Pima Indians with type 2 diabe- proximal tubular cells undergo hypertrophy, as defined
tes [16]. Cell culture studies on endothelial cells derived by increased cell size and protein content and by stimula-
from nonglomerular beds revealed a decrease in prolifer- tion of protein synthesis and collagen production [62, 63].
ation in the presence of high-glucose–containing medium
[53, 54], and this phenomenon could contribute to the
ROLE OF TRANSFORMING GROWTHextrarenal vascular dysfunction encountered in diabetes
FACTOR-b AND OTHER GROWTH FACTORSmellitus [55]. Studies are underway to characterize spe-
Several growth factors, cytokines, chemokines, andcifically the effects of high ambient glucose on the growth
vasoactive agents have been implicated in the pathogen-of glomerular endothelial cells.
esis of diabetic nephropathy (Table 2). The contributionDespite the demonstration that high glucose stimu-
of various growth factors to diabetic hypertrophy haslates fibronectin synthesis in cultured visceral glomerular
been recently reviewed [64, 65]. High glucose and itsepithelial cells [56], the profile of growth of these cells
metabolites, nonenzymatic glycation products, and he-in the diabetic milieu has not been thoroughly investi-
modynamic changes can all stimulate the synthesis andgated. A widely held postulate is that podocytes rarely
release of a host of factors from resident renal cellsreplicate in vivo, possibly because of continuous overex-
[64–66]. These factors may, in turn, through autocrinepression of cell cycle-arresting proteins [57, 58]. Podo-
and paracrine mechanisms, stimulate either proliferationcytes typically cope with injury or an alteration in homeo-
or hypertrophy of cells, as well as increase their produc-stasis by undergoing hypertrophy or apoptosis rather
tion of extracellular matrix proteins.than mitosis [58]. Hypertrophy of podocytes with broad-
ening of their foot processes, associated with a loss in
Transforming growth factor-btotal number per glomerulus, has been recently de-
This cytokine plays a central role in the developmentscribed in patients with type 2 diabetes [16]. Such hyper-
of renal hypertrophy and accumulation of extracellulartrophy may eventually lead to a degenerative process in
matrix components in diabetes mellitus. Evidence forthe glomerular visceral epithelial cells that underlies the
its involvement in these processes has been extensivelydevelopment of proteinuria and glomerulosclerosis in
reviewed [66, 67]. In brief, increased renal TGF-b expres-diabetes [59].
sion occurs in vivo in experimentally induced diabetesAlthough there is clear evidence from morphometric
as well as in diabetic humans [66–75]. Cultured mesangialstudies that isolated tubular epithelial cell hypertrophy
and proximal tubular cells exposed to high-glucose–(without prior proliferation) is a prominent feature of
containing medium synthesize more TGF-b than controlthe development of nephromegaly in the adult organism
cells grown in normal-glucose medium [46, 74]. Interest-[60, 61], some studies, almost exclusively performed in
ing recent studies have described that intracellular glu-streptozotocin-induced diabetes, have reported an in-
cosamine production resulting from glucose metabolismcrease in tubular mitosis [9, 43]. This tubular prolifera-
is responsible for increased TGF-b1 production in mes-tion is likely caused by streptozotocin, which is poten-
angial cells grown in high-glucose media [76]. Severaltially toxic to tubular epithelial cells [61]. It is also
vasoactive factors such as Ang II [77], endothelin-1 [32,possible that cellular proliferation may accompany hy-
pertrophy in younger animals. We have found that in 65], and thromboxane [78] may exert part of their
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growth-stimulatory and profibrogenic actions in diabetic regenerative liver and kidney growth subsequent to in-
jury, and its tyrosine kinase receptor, the protein productrenal disease through the secondary induction of TGF-b.
Furthermore, nonenzymatic glycation reactions leading of the c-met oncogene, are both stimulated in the kidney
of diabetic rats [90]. Immunohistochemistry has revealedto advanced glycation end products (AGE) [79], as well
as the early Amadori-glucose adducts in proteins such an increase of c-met protein in tubular cells, especially in
the distal tubule [90]. In addition, high-glucose mediumas serum albumin [80], have been shown to stimulate
renal expression of TGF-b [81]. Amadori glucose ad- mimics the induction of HGF in cultured proximal tubu-
lar and inner medullary collecting duct cells [90]. On theducts in albumin also increase expression of TGF-b type
II receptor mRNA and protein levels in mesangial cell other hand, cultured aortic endothelial cells exposed to
high-glucose media express less HGF than cells exposedcultures [81]. Parallel processes involving intrarenal he-
modynamic changes such as increased glomerular capil- to normal-glucose media [91]. The significance of these
findings is not currently clear; neutralization or inhibitorlary pressure [82, 83] can also stimulate TGF-b produc-
tion. Thus, a multitude of pathophysiological changes studies will be required to define the exact role that HGF
may play during diabetic hypertrophy. Besides, HGF isassociated with the diabetic state act in concert to induce
this cytokine [84]. High ambient glucose in mesangial a strong mitogen in cultured tubular cells [92], but as
reviewed earlier in this article, these cells typically un-cells also up-regulates the type II TGF-b receptor (the
signaling receptor that directly engages the ligand), fur- dergo hypertrophic growth in vivo with only a small
component of hyperplasia in the diabetic state.ther enhancing the bioactivity of TGF-b (abstract; Mogy-
orosi et al, J Am Soc Nephrol 7:1875, 1996). Interestingly,
Insulin-like growth factor-Ithe angiotensin-converting enzyme (ACE) inhibitor cap-
Several lines of evidence suggest that insulin-liketopril inhibits high-glucose–mediated hypertrophy in tu-
growth factor-I (IGF-I) may be involved in diabetic renalbular LLC-PK1 cells and also reduces the increased pro-
growth [93–99]. Renal IGF-I protein level, but not itstein expression of types I and II TGF-b receptors [85].
transcript level, is elevated during the early phase ofNeutralization studies in vivo and in vitro applying spe-
development of renal growth in experimentally inducedcific anti–TGF-b antibodies have provided clear evi-
diabetes [93–95]. This increase in renal IGF-I content isdence that induction of TGF-b, stimulated by the dia-
not associated with elevated circulating levels of growthbetic milieu, is necessary for renal hypertrophy and the
hormone or IGF-I [96]. In addition, the expression ofaccumulation of extracellular matrix proteins in the kid-
IGF-I receptor mRNA and total binding of IGF-I to itsney [46, 81, 84, 86]. Most recently, we also found that
receptor are both increased 14 days after induction oftubular epithelial cells obtained from TGF-b1 knockout
diabetes [97]. In situ hybridization studies have revealedmice failed to undergo hypertrophy and the stimulation
that the increase in IGF-I receptor mRNA expressionof collagen synthesis when cultured in high-glucose me-
in diabetic rats is principally localized to glomerular en-dium (abstract; Hoffman et al, J Am Soc Nephrol 8:497A,
dothelial and mesangial cells, as well as collecting ducts1997). Taken together, an enlarging body of evidence
[98]. Flyvbjerg et al demonstrated that long-term treat-derived from in vivo and in vitro studies indicate that
ment of diabetic rats with the somatostatin analogueincreased renal levels of TGF-b and the up-regulation
octreotide (which antagonizes release of growth hor-of its signaling receptors mediate diabetic renal growth
mone and therefore lowers tissue IGF-I levels) reducesand the accumulation of extracellular matrix proteins.
the increase in kidney weight [99]. However, because
Platelet-derived growth factor-B IGF-I is clearly a mitogen for cultured mesangial cells
[100] and proximal tubular cells [101], IGF-I accumula-Up-regulation of mRNAs encoding the PDGF-B
chain and the corresponding PDGF-b receptor has been tion in the kidney probably represents a more permissive
general factor for maintenance of adequate renal growthreported in glomeruli from diabetic rats, as well as in
mesangial cells exposed in culture to high glucose me- rather than a specific factor for the induction of diabetic
renal hypertrophy. Recent studies have disclosed thatdium [44, 87, 88]. This cytokine system has been shown
to stimulate TGF-b synthesis in renal cells [89]. Because IGF-I can probably act as a cofactor in modulating renal
tubular growth in the diabetic proteinuric state becauseexpression of PDGF-B coincides with mesangial cell pro-
liferation [44], it is likely that this potent mitogen stimu- serum-derived IGF-I leaks from the filtrate into the tubu-
lar fluid bound to transport proteins [102]. Further stud-lates early mitosis of glomerular cells with subsequent
induction of TGF-b, which, in turn, inhibits proliferation, ies are certainly needed to unveil the complex effects of
growth hormone, IGF-I, and IGF-I binding proteins onstimulates hypertrophy, and increases collagen produc-
tion [89]. renal growth in diabetes.
ChemokinesHepatocyte growth factor
Recent investigations indicate that expression of hepa- An interesting finding is the increased infiltration of
monocytes/macrophages into the glomerulus early in di-tocyte growth factor (HGF), a chief effector mediating
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abetes [44]. Some observations in diabetes demonstrate a decrease in protein catabolism may also contribute
significantly to cell enlargement and increased total cellu-that there is stimulated production of chemokines, che-
motactic factors for leukocytes, and monocytes/macro- lar protein content, which define cellular hypertrophy
[26]. There is compelling evidence that decreased proteinphages, indicating that these factors may mediate the
glomerular influx of immunocompetent cells [103–105]. degradation is involved in diabetic hypertrophy [122,
123]. Several studies have demonstrated that intracellu-A suggestive, albeit unproved, hypothesis is that the re-
lease of key growth factors and cytokines from these lar proteases (for example, cathepsins) are decreased in
their activity in the diabetic state [122–124]. Althoughmonocytes/macrophages (for example, interleukin-8 and
monocyte chemotactic peptide-1) may contribute to local the detailed mechanism for this proteinase inhibition is
currently not known, it is likely that growth factors suchchanges (for example, promotion of glomerular growth)
in diabetes. as Ang II and/or TGF-b are partly responsible [112, 123,
124]. These findings support the view that inhibition of
Angiotensin II proteolytic enzymes can decrease protein turnover and
this can contribute significantly to renal hypertrophy inIt has become well accepted that vasoactive sub-
stances, such as Ang II, can exert growth stimulatory diabetes.
actions on renal parenchymal cells, partly through the
release of other growth factors [31, 106]. The role of
SIGNAL TRANSDUCTION PATHWAYS IN
Ang II in diabetic nephropathy has been recently re-
DIABETES RELEVANT TO RENAL GROWTH
viewed [107, 108] and is not covered here in great detail.
Homeostatic disturbances in the diabetic state directlyIn brief, although originally thought to be suppressed in
influence many signal transduction pathways, but an ex-diabetes, there is increasing evidence that the intrarenal
haustive account is beyond the scope of this review.renin-angiotensin system (RAS) is activated in diabetic
However, a few issues related to signal transduction pro-nephropathy [108]. Hyperglycemia acts in synergy with
cesses in renal growth should be mentioned. One oflocally increased Ang II levels in stimulating renal hyper-
the most widely appreciated phenomena is activation oftrophy and the synthesis of extracellular matrix proteins
protein kinase C (PKC), which occurs in the kidney[109, 110]. Part of the mechanism of how Ang II potenti-
within days after development of diabetes [125, 126].ates the effects of high glucose is through their costimula-
Studies in cultured renal cells have demonstrated thattory actions on TGF-b induction [77] as well as the coin-
high concentrations of glucose activate PKC, most likelyhibition of proteinases that can slow the turnover of
by stimulating the intracellular de novo synthesis of theproteins [111, 112]. Moreover, hyperglycemia can en-
PKC activator diacylglycerol. The latter reaction ishance the expression of Ang II receptors and also reduce
driven by increased NADH/NAD1 ratio, thus shuntingthe degradation of Ang II by inhibiting Ang II-degrading
some glycolytic intermediates into the phosphatidic acid-enzymes, therefore increasing the local effects of Ang
diacylglycerol pathway [32, 125]. The increased NADH/II [112–114]. Both ACE inhibitors and AT1-receptor
NAD1 ratio can result from increased glucose metabo-blockers partially prevent renal hypertrophy in diabetes,
lism through the polyol pathway, catalyzed by the succes-and these drugs are currently the only available ones
sive actions of aldose reductase and fructose dehydroge-in humans for indirectly antagonizing TGF-b’s effects
nase. At least 11 isoforms of PKC have been characterizedthrough interfering with the RAS [115–118].
[126]. On the basis of structural similarities, these iso-
forms can be grouped into classic PKC (a, b1, b2, g), novelEndothelins and thromboxane
PKC (d, e, h, u), and atypical PKC (z, l). Recent evidenceThe vasoconstrictor endothelin-1, like Ang II, also
suggests that diabetes and high-glucose levels may acti-appears to be involved in diabetic renal growth; treat-
vate distinct isoforms in specific tissues [126]. For exam-ment of diabetic rats with endothelin receptor A antago-
ple, some investigators found activation of PKCa and b1nists reduces the expression of PDGF-B chain and
in membrane fraction of glomeruli isolated from diabeticTGF-b and prevents glomerular growth [119, 120]. Some
animals [126]. Kikkawa et al described activation oflimited evidence also suggests that increased prostanoid
PKCa and PKCz, which is independent of diacylglycerolproduction (for example, thromboxane) may contribute
accumulation [127]. In a detailed study on the alteredto the early proliferation of mesangial cells observed in
expression and subcellular localization of diacylglycerol-diabetic glomerulopathy [121].
sensitive PKC isoforms in diabetic rat glomerular cells,
Babazono et al reported stimulation of PKC activity and
DECREASED PROTEIN TURNOVER a significant increase in membrane-associated PKCa,
IN HYPERTROPHY PKCd, and PKCe [128]. Although this issue is not yet
settled, activation of different PKC isoforms in the kid-Many studies investigating renal hypertrophy have tra-
ditionally focused on stimulated protein synthesis, yet ney in a cell-specific manner may explain some of the
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differences in the growth response of individual cells mitosis (M phase; Fig. 1). The relevance of these mecha-
nisms to kidney diseases has been recently reviewedduring the course of diabetic renal disease.
[139], but a word of caution is in order regarding theThere are several important consequences to PKC
applicability of knowledge on the cell cycle derivedactivation that are relevant to diabetic renal hypertro-
mostly from in vitro work to the in vivo situation. Aphy. PKC activation can mediate activation of phospholi-
complex oscillation pattern of expression of variouspase A2, leading to release of membrane-bound arachi-
cyclins, changes in phosphorylation pattern of key pro-donate, which is further metabolized to prostanoids [121,
teins, and activation of distinct phosphatases control the125]. On the other hand, PKC activation plays an impor-
kinetics of the cell cycle [138–140]. The organized eventstant role in the bioactivation of TGF-b and the stimula-
during progression of cells through the cell cycle requiretion of extracellular matrix protein synthesis [129–131].
the activation of cyclin-dependent kinases (CdK). TheseActivation of the PKC system resulting from membrane
CdKs are associated with cyclins and exert, as a complexreceptor engagement by growth factors such as Ang II,
with the appropriate cyclin, kinase activity [139]. Re-endothelin-1, or thromboxane may be additive to the
cently, a group of novel proteins called CdK inhibitors,activation of the PKC enzyme systems resulting from
which bind and inactivate certain cyclin-CdK complexes,hyperglycemia-induced diacylglycerol generation. In ad-
has been identified [140]. For cells to proliferate, they
dition, PKC is involved in the high-glucose–mediated
must successfully progress through all of the phases of
mesangial cell F-actin disassembly, which may be neces- the cell cycle and must complete mitosis. For progression
sary for shape changes and growth of the cell [132]. through the G1 phase, complexes of CdK2 and cyclin ERecent investigations have linked renal PKC activation as well as the CdKs 4 and 6 bound to various D-type
in diabetes to the mitogen-activated protein kinase cyclins need to be in the active state (Fig. 1). In contrast,
(MAPK) pathway [133]. The MAPK cascade is an impor- cells undergoing hypertrophy are arrested in the G1-
tant intracellular signal transduction pathway leading to phase of the cell cycle with an inhibition of the G1-phase
cell growth. Activation of MAPK in glomeruli obtained active CdK-cyclin complexes that prevents transit into
from diabetic animals and mesangial cells grown in high S [41, 139].
glucose is mediated by PKC and appears to be important We have previously shown that mesangial cells, sub-
in cell proliferation and/or hypertrophy [133, 134]. Of jected to hypertrophy after prolonged incubation in high-
interest is the demonstration that AGEs can activate glucose medium, are arrested in the G1 phase [46]. Con-
MAPK pathways in tubular LLC-PK1 cells [135]. sequently, quiescent cells in the G0 phase must enter the
Other intracellular metabolic and signaling pathways G1 phase in order to undergo hypertrophy, but the cells
remain arrested in G1 phase. Immediate early genes inmay be linked to renal growth in diabetes. For example,
the kidney, which are expressed in the G1 phase, areit has been demonstrated that the polyamine pathway
induced early during the course of experimental diabetesmay be involved in diabetic renal growth. The path-
[46]. Moreover, the observation that high-glucose–way’s key intracellular enzyme, ornithine decarboxylase
induced expression of the immediate early genes c-fos,(ODC), is greatly stimulated in the kidney shortly after
c-jun, and Egr-1 in cultured mesangial cells indicates thatdiabetes induction [136]. Moreover, the inhibition of
these cells have entered the G1 phase [46, 141–143]. TheODC with difluoromethyl ornithine prevents the devel-
protein products of c-fos and c-jun form a leucine zipperopment of renal hypertrophy, suggesting that polyamine
heterocomplex called AP-1 and bind to a seven base-pairformation is essential for growth mechanisms in diabetes
consensus sequence, which is present in the promoter/[137]. Other studies have suggested that increased accu-
regulatory regions of many genes [143]. Furthermore,mulation of glycosphingolipids (for example, glucosyl-
recent studies demonstrate that post-translational modi-ceramide and ganglioside GM3) in the kidney may medi-
fications, induced by high glucose, also increase binding
ate the renal hypertrophy in streptozotocin-induced
of AP-1 to the consensus sequence [144]. This can poten-
diabetes in the rat [138]. tially bring about a multitude of cellular responses de-
pending on the context. However, hypertrophying cells,
expressing early G1 phase genes such as c-fos and c-jun,CELL CYCLE REGULATION DURING
do not progress into S [46]. Failure to enter into the S
DIABETIC RENAL GROWTH
phase may relate to the presence of potent inhibitors of
Regulation of the cell cycle is the pivotal element cell cycle progression. In fact, we have recently investi-
controlling whether quiescent cells are committed to mi- gated whether high-glucose–containing medium may in-
tosis. After being activated, for example, by growth fac- fluence expression of p27Kip1, a CdK inhibitor responsible
tors, quiescent cells enter the cell cycle from the G0 for arresting cells in G1 phase by inhibiting cyclin D-
phase, pass through G1, initiate their DNA synthesis CDK4, cyclin D-CDK6, and cyclin E-CDK2 complexes
[145]. Incubation of mouse mesangial cells, in the ab-in the S-phase, and after progressing through G2, enter
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Fig. 1. Overview of cell cycle regulation. In
order to proliferate, cells must enter the cell
cycle from a quiescent G0 phase, progress
through all the remaining phases (G1, S, G2),
and successfully complete mitosis (left side
of the figure). In contrast, cells undergoing
cellular hypertrophy, for example, in diabetic
nephropathy, actively enter the cell cycle but
do not progress beyond the late G1 phase.
Heterodimeric complexes of cyclin E-CdK2,
and cyclins D1-D3-CdK4,6 have kinase activi-
ties and drive cells through G1 into the S phase
by phosphorylating target proteins, including
the protein product of the retinoblastoma
gene (top of right side of figure). CdK-inhibi-
tors such as p27Kip1 or p21 bind to cyclin-CdK
complexes and inhibit their kinase activity
(bottom of right side of figure). Increased ex-
pression of p27Kip1 protein by hyperglycemia
arrests cells in the late G1 phase of the cell
cycle and therefore facilitates cellular hyper-
trophy as well as protect against apoptosis.
sence of other factors, for 48 to 96 hours in medium
containing high concentrations of d-glucose, stimulated
p27Kip1 protein expression, as detected by immunoblots,
but failed to influence mRNA abundance. These effects
were independent of the increased osmolarity of the
medium [145]. High-glucose–stimulated expression of
p27Kip1 was partly dependent on induction of TGF-b be-
cause a neutralizing anti–TGF-b antibody prevented, to
some extent, the expression of this CdK inhibitor [145].
Additional experiments revealed that activation of PKC
is essential for the high-glucose–induced expression of
p27Kip1 [145]. The high-glucose–induced p27Kip1 protein
preferentially associates with CDK2 but not with CDK4.
Fig. 2. Pivotal role of the CdK-inhibitor p27Kip1 in diabetes-inducedTransient transfection of mesangial cells with p27Kip1 anti-
hypertrophy of renal cells. High glucose, through activation of proteinsense oligonucleotides, but not missense, inhibited high
kinase C (PKC), as well as induction of TGF-b, leads to stimulation of
glucose-stimulated total protein synthesis and facilitated expression of p27Kip1 protein. Additional factors such as angiotensin II
(Ang II), and perhaps hemodynamic stretch and glycated proteins suchG1-phase exit [145].
as advanced glycation end products (AGE) may further stimulate p27Kip1We have further extended these studies to the db/db
expression. When the total amount of p27Kip1 protein is increased, there
mouse, a model of diabetes mellitus type 2. Glomerular is increased binding to cyclin-CdK complexes, inhibition of their activity,
and cell cycle arrest in the G1 phase, with subsequent development ofp27Kip1 protein, but not mRNA expression, was strongly
cellular hypertrophy. Additional CdK-inhibitors such as p21 may alsoincreased in diabetic db/db mice compared with nondia-
contribute to this G1-exit block. It remains unclear whether or not the
betic db/1 littermates [146]. Immunohistochemical stain- G1-phase arrest is a prerequisite for matrix accumulation, a classic
hallmark of diabetic nephropathy.ing revealed that mesangial cells and podocytes strongly
express p27Kip1 in diabetic mice [146]. Mesangial cells
derived from db/db and db/1 mice and grown in normal-
glucose medium showed only very little p27Kip1 expres- studies by Kuan, Al-Douahji, and Shankland suggest that
sion and thus were able to progress successfully through glomerular expression of p21, another CdK-inhibitor,
the cell cycle. However, raising the glucose concentration is increased in glomeruli of mice with streptozotocin-
in the medium led to G1-phase arrest in mesangial cells induced diabetes [147]. These investigators also found
derived from both db/db as well as db/1, and this was that high-glucose medium strongly stimulated expression
associated with induction of p27Kip1 protein [146]. These of p21 (but not p57 or p27Kip1) in cultured rat mesangial
findings strongly suggest that the increased glomerular cells [147]. Despite some discrepancies in experimental
p27Kip1 expression and the development of glomerular findings [146, 147], a picture is evolving in which CdK-
hypertrophy in db/db mice in vivo are due to hyperglyce- inhibitors are directly induced by high glucose through
PKC activation and stimulation of TGF-b (Fig. 2). Thesemia per se and not due to other factors [146]. Recent
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CdK inhibitors such as p27Kip1 and p21 bind to and inhibit cell hypertrophy is characterized by cell cycle arrest in
the G1 phase and is often followed by increased deposi-cyclin-CdK complexes and arrest cells in the G1 phase
of the cell cycle, thus facilitating cellular hypertrophy. tion of extracellular matrix proteins. Hypertrophy of re-
nal cells precedes and may arguably contribute to theAdditional stimuli for the induction of p27Kip1 in mesan-
gial cells include Ang II [148] and possibly shear stress late abnormalities of end-stage diabetic kidneys such
as glomerulosclerosis, tubular atrophy, and interstitialand protein glycation products (Fig. 2), but additional
studies are required to define the role of these stimuli fibrosis. Cell culture approaches, without interference
from hemodynamic or systemic factors, have providedin this process. Whether expression of p15, another CdK-
inhibitor that is stimulated by TGF-b, is altered in diabe- a considerable amount of insight into the mechanisms
of growth and the influence of high ambient glucose.tes will require additional studies. It is currently unclear
whether the induction of CdK inhibitors and the arrest A detailed analysis of renal growth in experimentally
of cells in the G1-phase during the process of hypertrophy induced diabetes in rodent models as well as in cultured
are also necessary steps for the accumulation of extracel- renal cells exposed to high ambient glucose has revealed
lular matrix proteins in diabetic renal disease. a different pattern of growth in mesangial cells as com-
pared with tubular epithelial cells. In the glomerular
compartment, there is no discernible apoptosis, but aAPOPTOSIS IN DIABETIC RENAL GROWTH
very early and self-limited degree of proliferation of mes-
Apoptosis is an active mode of cell death and may angial cells with subsequent cellular hypertrophy, which
contribute to the late structural abnormalities of the dia- remains prominent and sustained. Proximal tubular epi-
betic kidney, including tubular atrophy and tubulointer- thelial cells in the adult animal primarily undergo hyper-
stitial fibrosis [149]. A detailed account of potential apo- trophy, with occasional tendency to apoptotic stress, al-
ptotic mechanisms is beyond the scope of this review, though they seem to be protected against apoptosis.
but the process of apoptosis is tightly regulated by the Hypertrophy of the proximal tubule largely accounts for
activation of distinct genes, and some gene products such the clinically discernible nephromegaly of the diabetic
as the bcl-2 protein are protective against apoptosis [150]. state. Principally, high ambient glucose per se is a major
In a recent study, we found a significant increase of stimulus for growth of renal cells in diabetic renal dis-
apoptotic cells in the tubulointerstitium (but not glomer- ease. It is possible that specific membrane glucose trans-
uli) of db/db mice compared with nondiabetic littermates porters enhance the uptake of glucose and, hence, its
[151]. This increase in apoptosis was associated with a availability for intracellular metabolism. A major action
decrease in bcl-2 expression and an increase in bax gene of high intracellular glucose is the increased synthesis
expression, which predisposes to cell death by binding and release of growth factors, which then stimulate the
to and inhibiting bcl-2 [151]. In parallel, high-glucose
growth of renal cells through autocrine/paracrine mecha-
incubation of cultured proximal tubular cells decreased
nisms. There is overwhelming evidence from in vivo and
bcl-2 but increased bax expression [151]. An interesting,
cell culture studies that induction of the TGF-b systemalbeit unproved, hypothesis is that the early hypertrophy
is pivotal for hypertrophy of mesangial and tubular cells.of tubular cells may facilitate apoptosis by arresting cells
The molecular mechanism arresting the hypertrophyingin the G1 phase of the cell cycle and exposing them longer cells in the G1 phase of the cell cycle is the induction ofto apoptotic conditions without the opportunity of cell
CdK inhibitors such as p27Kip1 and p21, which bind torenewal through the progression in the cell cycle. In
and inactivate cyclin-CdK complexes responsible for G1-contrast to tubular cells, there is no evidence that high
phase exit. High glucose-induced activation of PKC andambient glucose in tissue culture or in vivo induces apo-
stimulated TGF-b expression appear to be required forptosis of mesangial cells [151]. Recent studies of glomer-
stimulated expression of p27Kip1. In addition, a decreasedular hypertrophy have shown that glomeruli of streptozo-
turnover of cell protein caused by inhibition of proteasestocin-diabetic mice do not display any evidence for either
contributes to hypertrophy. However, diabetic renalincreased cell proliferation (PCNA staining) or apopto-
hypertrophy cannot be only seen as one feature ofsis (terminal deoxynucleotidyl transferase-mediated nick
TGF-b’s many effects because other growth factors suchend-labeling). Because p21 and p27Kip1 proteins can have
as the growth hormone/IGF-I axis are clearly importantantiapoptotic functions [147, 151, 152], then it is possible
in renal growth during the course of diabetic nephropa-that the increased levels of p21 and p27Kip1 proteins that
thy. Other factors such as protein glycation products,are observed in the diabetic kidney are protective against
hemodynamic forces, and vasoactive factors (Ang II,renal cell apoptosis.
endothelin-1, and thromboxane) may further amplify the
synthesis of growth factors and the expression of their
CONCLUSION receptors in the diabetic state. Induction of PDGF-B
and its b-receptor, for example, may contribute to theHypertrophy of mesangial and proximal tubular cells
is an early hallmark of diabetic renal involvement. This very early proliferation of mesangial cells.
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